Navigation Links
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Date:5/7/2009

Conference Call Scheduled for Today - Thursday, May 7, 2009 at 5:30 p.m. Eastern Time

MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for the quarter ended March 31, 2009, and provided an update on its product candidates. The net loss for the quarter, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $6.9 million compared to a net loss of $18.4 million in the comparable period in 2008. Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) at March 31, 2009 of $40.7 million.

"During the first four months of 2009, we have continued to keep pace with our AZ-004 (Staccato(R) loxapine) NDA timeline," said Thomas B. King, President and CEO of Alexza. "Our clinical and regulatory plan is on track, as is the continued scale-up of our commercial manufacturing and quality systems processes. We continue to target our AZ-004 NDA submission for the first quarter of 2010."

Financial Results - Periods Ended March 31, 2009 and 2008

GAAP operating expenses were $16.4 million and $19.2 million in the quarters ended March 31, 2009 and 2008, respectively. In January 2009, the Company announced that it had consolidated its operations, with a primary focus on the continued development of AZ-004 (Staccato loxapine). The restructuring included a workforce reduction of 50 employees, representing approximately 33% of the Company's total workforce. With the reduction in headcount and focus on the development of AZ-004, the Company expects to reduce its expenses by approximately $21.5 million, net of severance costs, for fiscal year 2009, compared to fiscal year 2008, and another reduction of appr
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
2. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
3. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
4. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
8. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
9. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
10. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
11. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Premune and Innovet ... licensing agreement for Redonyl ® Ultra. The product, ... veterinary dermatology market, is a nutritional supplement based on ... in dogs and cats. Redonyl ® Ultra is ... has been received positively in the country by veterinarians ...
(Date:8/31/2015)... PLEASANTON, Calif. , Aug. 31, 2015  QT Vascular ... "QT Vascular", and together with its subsidiaries, the ... assembly and distribution of advanced therapeutic solutions for ... today the final results of the below-the-knee ("BTK") ... Registry ("BAR") which were presented on August 15, ...
(Date:8/31/2015)... Aug. 31, 2015   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell ... cryopreservation freeze media and a related ... for smart shippers ("BioLife" or the ... an advanced biopharmaceutical company focused on developing and ...
Breaking Medicine Technology:Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
... Va., Feb. 9, 2011 With generous funding ... Palliative Care Association are partnering to improve pain ... hospitals in The Gambia, Kenya, and Malawi. ... they each have well-established national palliative care organizations, ...
... Design Trends: Technological Advances in Implantable Devices, a UBM Canon Medical Device ... Industry ( MD+DI ) , ... , and OrthoTec , is now on-demand ... 1,092, with an attendance of 50% during the live event held on ...
Cached Medicine Technology:FHSSA and the African Palliative Care Association Launch the First-Ever Pain Management Initiative in The Gambia, Kenya, and Malawi 2Now Available: Archived Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices 2Now Available: Archived Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... borders seldom arise at the most convenient time for everyone involved. These occasions ... help. , Universal Translation Services has real people available to handle ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully placed one of the ... the last month the FDA has approved two intra-gastric balloons, the ORBERA ™ ... the first incisionless, reversible, weight loss procedures available to Americans. , Dr. ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... to send information about new patients directly from Practice Perfect to FOTO enabling ... data entry. , Steven Presement, President of Practice Perfect, stated ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Anthony J. Tantillo, ... Super Lawyers 2015 for his third consecutive year in a row. Through nomination, ... of helping people. , Born in Niagara Falls, New York, Tantillo is a Buffalo ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Zeel™, has recently sponsored an educational workshop for physician assistants (PAs) practicing in ... of Traumeel™ and Zeel™” was held by Dr. Erick Salado, an orthopedic surgeon ...
Breaking Medicine News(10 mins):Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... NEWPORT BEACH, Calif., Feb. 7 Nationwide,Health Properties, Inc. ... will,release its fourth quarter earnings on Monday, February 25, ... Stock Exchange. The Company will host a,conference call on ... a.m. Eastern time) in order to present the Company,s ...
... Breast Cancer Movement Gathers Record Attendance for Annual ... ... Susan G. Komen for the Cure(R), the,world,s largest and most progressive ... Affiliate Leadership,Conference Feb. 7-9 at the Hilton Anatole in Dallas. The ...
... in Florida and one in Kansas, SANTA ... REIT, Inc. has acquired Medical Portfolio 1. The ... 1 consists of five medical office buildings, Doctor,s,Medical ... Brandon,Medical Plaza and Central Florida SurgiCenter. The portfolio, ...
... PICK: VEGF-B helps nerve cells cheat death without unwanted side ... family of proteins, VEGF, has recently been shown to protect ... its clinical utility in this regard is limited, because it ... In a new study, Xuri Li and colleagues at the ...
... High-Value Jobs For Commonwealth, HARRISBURG, Pa., Feb. ... better able to put promising Pennsylvania,pharmaceuticals, biotech, medical ... for growth, Governor Edward G. Rendell said, with ... sciences industry remains one of the most dynamic ...
... Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today ... President & Chief Executive Officer. In support of ... MPM,Capital, Great Point Partners, Oxford Biosciences and Venrock, ... who has served as the,Company,s President & Chief ...
Cached Medicine News:Health News:NHP Announces Fourth Quarter Earnings Release Date and Conference Call/Webcast 2Health News:NHP Announces Fourth Quarter Earnings Release Date and Conference Call/Webcast 3Health News:Susan G. Komen for the Cure(R) Hosts Annual Affiliate Leadership Conference in Dallas 2Health News:Susan G. Komen for the Cure(R) Hosts Annual Affiliate Leadership Conference in Dallas 3Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 1 2Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 1 3Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 1 4Health News:JCI online early table of contents: Feb. 7, 2008 2Health News:JCI online early table of contents: Feb. 7, 2008 3Health News:JCI online early table of contents: Feb. 7, 2008 4Health News:JCI online early table of contents: Feb. 7, 2008 5Health News:JCI online early table of contents: Feb. 7, 2008 6Health News:JCI online early table of contents: Feb. 7, 2008 7Health News:JCI online early table of contents: Feb. 7, 2008 8Health News:Pennsylvania Gov. Rendell: $10 Million Partnership With Harrisburg Venture Capital Firm Boosts PA's Life Sciences Industry 2Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 2Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 3Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 4
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
... is comprised of the TEG analyzer and the ... picture of the formation and dissolution of the ... two systems. ,Haemoscope's TEG analyzer is the only ... the reliable and proven model developed by Prof. ...
With BareWire technology, the wire crosses the lesion first, independent of the filter and delivery catheter. All other actions, including filter placement and retrieval, balloon dilatations, and ste...
... is supported on NT / 2000 platforms. ... to effectively work in a multi-user, networked ... move comfortably to an enhanced level of ... improving the quality of patient care. , ...
Medicine Products: